Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility

Novo Nordisk (NVO) posted a 32% revenue spike in Q1 2026 after launching its Wegovy weight-loss pill, but the momentum did not hold. Sequential declines followed in Q2 2026, driven by pricing pressure and ordering patterns.

Bristol Myers Squibb (BMY) has taken the steadier path. It led in seven of eight quarters over the past two years in revenue growth, a consistency NVO's swings cannot match.

The sharpest risk sits in NVO's mix. Ozempic and Wegovy account for 70% of sales, so any pricing or ordering disruption in those two products flows directly into the top line. The Q2 reversal shows how quickly that exposure can bite. BMY's growth portfolio is more diversified, which spreads that risk across multiple drivers.

Interpretation: the Q1 launch spike and Q2 pullback suggest NVO's quarterly prints may stay lumpy, while BMY's record points to lower revenue variance. That is a read on the supplied figures, not a forecast.

GLP-1 enthusiasm still drives investor interest in NVO, which keeps the stock sensitive to each quarterly datapoint.